Australia’s most promising digital and connected health companies can now apply to access up to $5 million in non-dilutive funding in the next round of ANDHealth+, the country’s leading commercialisation accelerator and incubator program for evidence-based health technologies.

Supported by the Australian Government through the Medical Research Future Fund (MRFF) Medical Research Commercialisation Initiative, ANDHealth+ provides selected companies with non-dilutive funding over an 18-month, two-stage program alongside hands-on support from a world-class network of experts to help them commercialise and scale their businesses. Up to five companies will be selected in this new application round.

The opening of applications follows ANDHealth’s landmark international recognition last week, with ANDHealth+ named a finalist in the 2026 Prix Galien USA Awards in the Best Incubators, Accelerators and Equity category.

ANDHealth is the first Australian commercialisation organisation, and the only APAC organisation, nominated in the accelerator/ incubator category for the prestigious global awards, which recognise excellence in health technology and life-sciences innovation. It is one of only 11 organisations worldwide shortlisted in the category, alongside leading global institutions including the Mayo Clinic. The Prix Galien USA winners will be announced on 29 October 2026.

“ANDHealth's nomination demonstrates the global impact and international competitiveness of our ANDHealth+ program,” ANDHealth Chief Executive Bronwyn Le Grice said.

“ANDHealth+ selects Australia's most promising companies and provide them with world-class commercialisation support, equity-free funding and an accelerated pathway to investment and global scale, with 93 per cent of all alumni companies raising follow-on funding.”

This opening follows the most competitive application round in the program’s history, with more than 90 companies applying for the prior intake, a 65 per cent increase on the average number of applications received across the preceding four application rounds. Five companies were selected to join ANDHealth+ earlier this year: Australis Scientific, Corcillum, Earflo, Kraken Coding and MoreGoodDays.

ANDHealth Chief Executive Bronwyn Le Grice said the record demand demonstrated both the strength of Australia’s innovation pipeline and the urgent need for expanded specialist support that helps these companies overcome the distinctly different commercialisation barriers they face.

“The response is a powerful signal of the depth of digital and connected health innovation being developed across the country, but it also reflects the reality that access to capital remains one of the greatest barriers facing companies seeking to translate evidence-based technologies into sustainable, scalable businesses.”

“ANDHealth+ exists to help high-potential companies build the clinical, commercial and technical evidence, partnerships and market pathways they need to become fit for investment and fit for deployment.”

ANDHealth+ is a non-equity-taking program designed for proof-of-concept or later-stage companies. It is structured to address the challenges unique to software-enabled and software-based health technologies, including the generation of clinical and economic evidence, regulatory and reimbursement strategy, enterprise sales readiness, data and technical validation, and international market entry.

“Digital and connected health technologies do not follow the same commercialisation pathway as traditional biopharmaceuticals or medical devices,” Ms Le Grice said.

“These companies need specialist support from people who understand the health system, the evidence expectations of customers and investors, and what it takes to turn a promising technology into a product or service that can be adopted at scale.”

“Our role is to help Australian companies grow locally and scale globally, creating high-value jobs, attracting investment and delivering technologies that make health and care more accessible, effective and sustainable.”

Collectively, the 28 alumni companies that have completed the ANDHealth+ program to date have raised more than $211 million in follow-on funding, generated more than $97 million in new revenue, created 558 jobs and impacted more than 4.7 million patients. For every dollar invested by government, the ANDHealth+ program has returned nearly $20 in new capital and created jobs at 14 times the international benchmark.

“The next ANDHealth+ cohort will give a new group of companies the opportunity to turn that potential into measurable impact – for patients, the health system and the Australian economy.”

Applications close on Monday 28 September 2026.

‍

Learn more about ANDHealth+